vtx logo

request clinical advice

vtx logo sticky

scott@vtx-cpd.com

Forum Replies Created

Viewing 15 posts - 1,756 through 1,770 (of 2,371 total)
  • Author
    Posts
  • scott@vtx-cpd.com
    Keymaster

    Replying to Claire L. 10/04/2022 - 11:06

    This is a brilliant question.

    I am going to chat to some ECC colleagues about this one too.

    The role of gastric protection medication in acute toxicity is not clear, even in human medicine as far as I am aware. Significant gastrointestinal hemorrhage secondary to acute overdose is likely to be uncommon. It is thought that upper gastrointestinal symptoms are self-limiting; however antiemetics may be required for those with persistent or severe nausea and vomiting. No studies, to my knowledge, have investigated the role of prophylactic use of antacid or acid-suppressants such as proton pump inhibitors. I might consider a short (7-day course) of a proton pump inhibitor in patients with acute NSAID overdose who have persistent upper gastrointestinal symptoms which do not settle within a few hours of ingestion. I would not be reaching for them routinely.

    I would consider misoprostol in these cases, although the evidence for this is also not great.

    Hope that helps.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to konstantinos C. 10/04/2022 - 16:52

    Hello Konstantinos.

    Hope you are well. In acute cases I would normally only give short course (up to 7 days). In chronic cases, I would use much longer term. You could even consider life long in some cases. Because so many of the chronic cases are dietary responsive, I would normally do that first. I would be moving quickly to introduce probiotics after this and certainly introducing probiotics in all cases that were receiving steroids. If I was then weaning medications in more chronic cases, I would consider keeping the probiotics going until all other medications had been discontinued.

    Hope that helps.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Christina Birks 09/04/2022 - 09:26

    Hello Christina.

    Thank you so much for joining the course.

    Your suggestions are great and I agree that these are definitely the most challenging cases when there is more than one thing is going on!!!

    Glad you enjoyed the first lesson.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Emma Holt 05/04/2022 - 13:12

    Good shout with the chlorphenamine!

    The FNA results were as follows:

    Cytology – lymph node
    MICROSCOPIC DESCRIPTION. Mildly increased numbers of eosinophils are present with lower numbers of nondegenerate neutrophils. Rare intermediate to large lymphocytes and plasma cells are noted. No infectious organisms or malignant cells seen.

    MICROSCOPIC INTERPRETATION: Slight eosinophilic to mixed inflammation.

    Cytology – gastric wall
    MICROSCOPIC DESCRIPTION. Increased numbers of eosinophils are present with lower numbers of nondegenerate neutrophils. No infectious organisms or malignant cells seen.

    MICROSCOPIC INTERPRETATION: Eosinophilic inflammation.

    We did go on to take biopsies:

    Histopathology – Gastrointestinal biopsies
    Stomach:
    Several sections of tissue consist of brightly eosinophilic material surrounding clusters of coccoid bacteria and encased in fibroplasia, epithelioid macrophages, neutrophils, and eosinophils. Special stains show no infectious organisms.
    These histologic lesions are most compatible with eosinophilic sclerosing fibroplasia.

    Duodenum:
    No histopathologic abnormalities

    Diagnosis? Treatment?

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Sophie I. 07/04/2022 - 16:28

    Hello.

    I have double checked with Jocep and it is not available in the UK.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Hello Nathalie.

    I am certainly a big fan. From my perspective, really useful in patient on steroids… and I have a lot of them.

    I recorded a podcast on this exact topic with an anaesthesia specialist:

    I am sure Kerry and Neus will have lots of insight with their more critical patients.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Julie S. 07/04/2022 - 11:34

    Hello!

    Lovely to see you here too. You will be busy with GI and endocrine at the same time!

    Thank you again for the support.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Sophie I. 07/04/2022 - 16:28

    Hello.

    Lovely to hear from you. I hope you are well.

    I am not 100% sure… but I know a man how will know!

    I will speak to Jocep and let you know!

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Raquel M. 24/03/2022 - 13:19

    Hey Raquel.

    I hope you are safe and well and having a lovely week. Thank you again for your brilliant questions. I have popped your questions below and my thoughts underneath. I did not want to miss anything:

    Hello,

    1) (a) what would you suggest for cases where an animal is reported to have a pinkish color in the vomitus or a few drops of blood as per O?

    This is a great question and challenging to give a definitive answer. I would say in acute cases, when patients are well otherwise, I would not jump to use a PPI. If the presence of blood continued despite symptomatic therapy (antiemetic), or there was evidence of melena, then I would consider the use of a PPI.

    (b) also if the owner reported the above was a one-off incident(or intermittent) and the other episodes of vomiting didn’t indicate any signs of blood then would you start with a PPi? Or only if the diagnostic workup confirmed GI ulceration?

    Again, I would probably not. In there cases when intermittent. Endoscopy/ultrasound would be perfect to confirm ulceration or not.

    Was just wondering if there’s not a substantial amount of frank blood in the vomitus and the pinkish color or specks of blood reported by owner aren’t persistent. Then is it appropriate to use PPIs or not? Especially if the owner is unable to complete a full workup to rule out ulceration.

    I think for small amounts I would be rushing to use. If this was persistent and the owners were not able to carry out much work up then I would consider a PPI.

    I hope that helps/makes sense.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Julie S. 04/04/2022 - 11:30

    Hello.

    The other thing that may be of benefit when assessing whether a proton pump inhibitor (or any other drug) has had a significant effect on the microbiome would be to consider the dysbiosis index:

    https://www.idexxbioanalytics.com/microbiome-analysis

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Julie S. 24/03/2022 - 11:37

    Hello.

    Great question! The main data is from the human literature. There are lots of paper. A example of a recent review:

    https://pubmed.ncbi.nlm.nih.gov/33560890/

    The following is from that review:

    Gut Dysbiosis

    A growing area of concern with chronic PPI use is the development of gut dysbiosis. Gut dysbiosis results after chronic suppression of gastric acid leads to an increased pH in the small intestine, causing an imbalance in the microbiota. This affects the metabolism of foods and medications and can lead to an inflammatory state due to increased gastrin. Gastrin level elevation is directly correlated to PPI dose; this is significant because patients often have their dosage increased until symptoms are controlled. The decrease in the pH of gastric content can also result in small intestinal bacterial overgrowth (SIBO) defined as overgrowth greater than 105 bacteria per mL. Small intestinal bacterial overgrowth is characterized by malabsorption, bloating, diarrhea, and weight loss. Changes in the microbiome include increases in Streptococcus, Staphylococcus, Escherichia, Bacteroides, Lactobacillus, and Clostridium.

    Overall, the effect on the microbiome is variable depending on the study. I would indeed chose the best probiotic, based on strains.

    I currently tend to use Vivomixx, as it is the same composition as what used to be VSL#3, which has the most evidence attached. This is also, as Sivomixx is currently not available for shipping to the UK, they have some licensing issues. Also, Vivomixx can be at room temperature for up to 7 days, which makes posting easier, but then it should go back in the fridge. Dosing is a bit arbitrary, I popped the dosing guide for Sivomixx in another post, which I use as a guide for Vivomixx as well.

    Hope that helps.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Kim Choo L. 05/04/2022 - 12:49

    Hello Kim.

    Lovely to hear from you! I am so glad that you are part of the course.

    Let me know if you have any questions at any time.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Natalie H. 06/04/2022 - 10:01

    Hey.

    The most evidence is actually for budesonide foam. It is used mostly in humans for ulcerative colitis:

    https://pubmed.ncbi.nlm.nih.gov/32189103/

    There is not data in dogs. I would consider this as an option in very refractory cases of colitis and proctitis. The biggest issue with this treatment is the tolerance of the patient!

    scott@vtx-cpd.com
    Keymaster

    Replying to Hannah B. 23/03/2022 - 17:25

    Hello.

    Thank you for your question. I hope you are having a lovely week. I popped the following information on our members forum and I thought it might be helpful:

    ”Cats with chronic upper respiratory disease/rhinitis can sometimes be really challenging to treat and become very congested. There are no scientific studies to support and describe the use of intranasal maropitant citrate, and this would be off-label use. The described use is done by diluting 1ml of maropitant to 9ml of saline (10% dilution) and using this as an intranasal drop. Most individuals that report anecdotal response are using 1-2 drops daily or every other day.

    The use of intranasal maropitant for cats is generally reserved for those with severe rhinitis (nasal congestion/inflammation), as maropitant is thought to directly target inflammation. Maropitant is a neurokinin-1 (NK1) receptor antagonist that acts in the central nervous system by inhibiting Substance P. Though maropitant is labeled for use to control vomiting, substance P has been documented to be released in the respiratory tract following inflammation or irritation.”

    Hope that helps.

    Scott πŸ™‚

    scott@vtx-cpd.com
    Keymaster

    Replying to Sybil Dryburgh 23/03/2022 - 13:34

    Hey.

    Great question. I will try and find some supporting literature. Furosemide certainly has more than just its diuretic effects.

    I will also ask Liz to comment as she has lots more experience with this drug.

    Scott x

Viewing 15 posts - 1,756 through 1,770 (of 2,371 total)